Aluminum Hydroxide Suspension

BIOLOGICAL4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19HIV InfectionsHIV-1Respiratory Syncytial Virus

Phase 1

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

CompletedNCT03049488

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus

Start: 2017-02-22End: 2019-10-03Updated: 2020-10-23

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

CompletedNCT04915768

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2023-01-23End: 2025-07-15Updated: 2026-02-27

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

SuspendedNCT06680479

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1

Start: 2025-04-01End: 2028-04-14Target: 30Updated: 2026-03-03

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

RecruitingNCT07221162

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2025-12-05End: 2026-11-24Target: 140Updated: 2026-04-03

Related Papers

Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)

medRxiv2026-04-03

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

2021-04-1453 citations